<DOC>
	<DOC>NCT00817622</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of EPA(Eicosapentaenoic Acid)alone and with VitE in diabetic patients.</brief_summary>
	<brief_title>Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM</brief_title>
	<detailed_description>Randomized, double-blind, placebo-controlled, parallel-group study design After a 12weeks, subjects with type II DM will be randomized to receive either 2000 mg pearl EPA per day plus a double-blinded matching placebo (1 corn oil pearls per day) for 12 weeks OR 400 mg VitE pearl plus double-blinded per day plus a double-blinded matching placebo (4 corn oil pearls per day) for 12 weeks OR 2000 mg pearl EPA per day plus a double-blinded matching 400 mg VitE pearl OR placebo(4corn oil pearls per day plus 1 corn oil pearls per day )for 12 weeks.The total dose of EPA pearl will be 2000 mg per day (with the EPA or matching placebo corn oil doses remaining at 4 pearls per day) and The total dose of VitE pearl will be 400 mg per day (with the VitE or matching placebo corn oil doses remaining at 1 pearls per day).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>DM Type II. Antidiabetic drug therapy which cannot be stopped. History of DM about 215 year. Age between 3055 year. No History of circulatory, thyroid, pulmonary, liver, kidney, cancer. DM Type I. Nephropathy. Retinopathy. Cancer. Thyroid disease. Renal failure. pulmonary disease MI. CHD. Liver disease,</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>EPA</keyword>
	<keyword>leptin</keyword>
	<keyword>adiponectin</keyword>
</DOC>